Nucleoside phosphonate salts
View Patent ↗The present invention relates to compounds and methods for treating viral diseases. Some compounds of the invention are described by Formula I: (I), wherein M + is Na + , Li + , K + , Ca 2+ , Mg 2+ , or NR c R d R e R f + and R c , R d , R e and R f are each independently hydrogen or C 1-5 alkyl, or a stereoisomer, a diastereomer, an enantiomer or racemate thereof.
1. A stable crystalline form of a compound of formula I:
or a stereoisomer, diastereomer, enantiomer or racemate thereof, wherein M + is Na + , Li + , K + , Ca 2+ , Mg 2+ , or NR c R d R e R f + , wherein R c , R d , R e and R f are each independently hydrogen or C 1-5 alkyl, and wherein the crystalline form of the compound is greater than 95% pure and retains greater than 95% purity after being kept at about 40° C. for four weeks.
2. The compound of claim 1 having the structure:
wherein M + is Na + , Li + , K + , or NH 4 + .
3. The compound of claim 2 , wherein M + is K + .
4. A pharmaceutical composition comprising a stable crystalline form of a compound of formula I:
or a stereoisomer, diastereomer, enantiomer or racemate thereof, and a pharmaceutically acceptable adjuvant, diluent, carrier, or excipient thereof, wherein M + is Na + , Li + , K + , Ca 2+ , Mg 2+ , or NR c R d R e R f + , wherein R c , R d , R e and R f are each independently hydrogen or C 1-5 alkyl, and wherein the crystalline form of the compound is greater than 95% pure and retains purity greater than 95% after being kept at 40° C. for about four weeks.
5. The pharmaceutical composition of claim 4 , wherein the compound has the structure:
wherein M + is Na + , Li + , K + or NH 4 + .
6. The pharmaceutical composition of claim 5 , wherein M + is K + .
7. The pharmaceutical composition of claim 5 , wherein the compound has purity greater than 96%.
8. The pharmaceutical composition of claim 5 , wherein the compound has purity greater than 97%.
9. The pharmaceutical composition of claim 5 , wherein the compound has purity greater than 98%.
10. The pharmaceutical composition of claim 5 , wherein the compound has purity greater than 99%.